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group and 32.7 cm3 (range: 17.8 -75.1) for the TUMT group. The median amount of remaining urine was 62 mL (range: 3 -520) for the TURP group, 25 mL (range: 5 -350) for the VLAP group and 14 ml (range: 2 -168) for the TUMT group. The median IPSS was 19 (range: 5 -35) for the TURP group, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] for the VLAP group and 17 (range: 7 -34) for the TUMT group.
Study design
This was a non-randomised study that was carried out in a single centre. The follow-up period was until the last day of the patients' hospital visit. No loss to follow-up was reported.
Analysis of effectiveness
The analysis of effectiveness was conducted on an intention to treat basis. The outcomes assessed were: the duration of hospitalisation, outpatient visits and follow-ups; the number of cases for reoperation; the use of alternative surgical methods; and complications.
In terms of baseline characteristics, the TURP group was observed to contain slightly more serious cases than the VLAP and TUMT groups, according to the volume of affected prostate and amount of remaining urine.
Effectiveness results
The median number of hospitalised days was 21 days (range: 14 -43) for the TURP group and 16 days (range: 7 -35) for the VLAP group.
TUMT was carried out without hospitalisation.
The median number of outpatient visits was 11 days (range: 1 -80) for the TURP group, 16 days (range: 1 -85) for the VLAP group and 14 days (range: 4 -71) for the TUMT group.
The median duration of follow-up was 12.4 months (range: 1.0 -71.8) for the TURP group, 46.7 months (range: 14.2 -129.8) for the VLAP group and 14.4 months (range: 1.0 -49.8) for the TUMT group.
Among the TUMT group, 4 patients needed reoperation (1 received an additional TURP), while 5 others needed an alternative surgical method (TURP or transurethral needle ablation).
In terms of slight postoperative complications, one case (stricture of urethra) was observed in the TURP group and two cases (stricture of urethra and inflammation of the testes) were observed in the VLAP group. No complications were observed in the TUMT group.
Clinical conclusions
TUMT had the shortest treatment period and had a shorter follow-up than VLAP, but it had the highest recurrence rate.
Measure of benefits used in the economic analysis
No summary measure of benefit was used in the economic analysis. Therefore, the health benefits were those associated with the effectiveness results. As such, a cost-consequences analysis was performed. The total medical costs for hospitalisation and outpatient treatments, exclusive of operation and anaesthetic fees, were presented using Japanese social insurance points. The quantities and the costs were not reported separately. Discounting was not carried out. The costs were calculated on the basis of the actual treatment payment details received by the hospital from the government. The costs for each patient were calculated from the month of their surgical operation until the last month of their hospital visit (if the patients were hospitalised before the operation, the costs were from the month of their hospitalisation). The price year was not stated.
Direct costs

Statistical analysis of costs
No statistical analysis of the costs was carried out.
Indirect Costs
No indirect costs were included.
Currency
Japanese social insurance points. These were not converted into a specific currency but were a proxy for resource usage/costs.
Sensitivity analysis
No sensitivity analysis was performed.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The median total costs were 59,395 points (range: 42, 651 -155,988) for the TURP group, 66,784 points (range: 36,169 -120,867) for the VLAP group and 14,927 points (range: 3,374 -84, 777) for the TUMT group
The total costs were divided by the treatment period (number of days) and follow-ups (number of months).
The median total costs were 1,822 points/day (range: 1,145 -2,492) and 1,733 points/month (range: 771 -214,013) for the TURP group, 2,104 points/day (range: 1,061 -2,849) and 2,104 points/month (range: 605 -95,405) for the VLAP group, and 1,197 points/day (range: 685 -2,175) and 1,390 points/month (range: 251 -23,139) for the TUMT group.
When the cases of reoperation and changes to other surgical methods were considered, the median costs for the TUMT group were 1,073 points/day (range: 685 -2,176) and 1,046 points/month (range: 251 -2,314) for the patients who did not need additional surgical treatments. The median costs were 1,167 points/day (range: 819 -1,287) and 1,403 points/month (range: 645 -1,878) for patients who had a reoperation, and 1,576 points/day (range: 1,222 -1,686) and 1,753 points/month (range: 1,523 -2,804) for those patients who needed changes to other surgical methods.
Synthesis of costs and benefits
Not applicable due to the cost-consequences approach adopted.
Authors' conclusions
Transurethral microwave thermotherapy (TUMT) was the most cost-effective method, followed by transurethral resection of the prostate (TURP). However, TUMT resulted in higher recurrence rates than TURP and visual laser ablation of the prostate (VLAP), leading to higher costs in some cases. Thus, the selection of surgical methods for benign prostatic hypertrophy (BPH) has to be carried out very carefully.
